170 related articles for article (PubMed ID: 24980806)
21. Interactions of cyclosporin a with breast cancer resistance protein.
Xia CQ; Liu N; Miwa GT; Gan LS
Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
[TBL] [Abstract][Full Text] [Related]
22. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
23. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
[TBL] [Abstract][Full Text] [Related]
25. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
26. [Establishment of BCRP expressed pig kidney cell line LLC-PK1/BCRP and its biological profile].
Tian Y; Qu BX; Yao Y; Zeng S
Yao Xue Xue Bao; 2012 Dec; 47(12):1599-604. PubMed ID: 23460964
[TBL] [Abstract][Full Text] [Related]
27. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
28. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
29. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
[TBL] [Abstract][Full Text] [Related]
30. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
31. The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?
Poirier A; Portmann R; Cascais AC; Bader U; Walter I; Ullah M; Funk C
Drug Metab Dispos; 2014 Sep; 42(9):1466-77. PubMed ID: 24989889
[TBL] [Abstract][Full Text] [Related]
32. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
33. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
34. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
Katoh M; Suzuyama N; Takeuchi T; Yoshitomi S; Asahi S; Yokoi T
J Pharm Sci; 2006 Dec; 95(12):2673-83. PubMed ID: 16892207
[TBL] [Abstract][Full Text] [Related]
35. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
36. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
37. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
38. The interaction between human breast cancer resistance protein (BCRP) and five bisbenzylisoquinoline alkaloids.
Tian Y; Qian S; Jiang Y; Shen Q; Zheng J; Zhou H; Zeng S
Int J Pharm; 2013 Sep; 453(2):371-9. PubMed ID: 23742976
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
40. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
Bae S; D'Cunha R; Shao J; An G
Eur J Pharm Sci; 2018 May; 117():27-34. PubMed ID: 29425861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]